Home › Compare › FGWLF vs ABBV
FGWLF yields 3.44% · ABBV yields 3.06%● Live data
📍 FGWLF pulled ahead of the other in Year 3
Combined, FGWLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FGWLF + ABBV for your $10,000?
Flughafen Wien Aktiengesellschaft, together with its subsidiaries, engages in the construction and operation of civil airports and related facilities in Austria. It manages the Vienna airport. The company operates through five segments: Airport, Handling & Security Services, Retail & Properties, Malta, and Other. The company's Airport segment operates and maintains aircraft movement areas and terminals, as well as equipment and facilities for passenger and baggage handling, as well as security controls for passengers. This segment also offers various services to support airport operations, deal with emergencies and disruptions, and ensure security. Its Handling & Security services segment provides various services for the handling of aircraft and passengers on scheduled and charter flights, as well as for the handling of general aviation aircraft and passengers. This segment also operates the general aviation center; and provides security controls for passengers and hand luggage. The company's Retail & Properties segment offers services that support airport operations, including shopping, food and beverages, VIP, lounges, and parking, as well as develops and markets properties. Its Malta segment operates Malta airport; and provides parking services, as well as rents retail and office space. The Other segment offers technical and repair, energy supply and waste disposal, telecommunication, and information technology, electromechanical and building, construction management, and consulting services, as well as construction and maintenance services for infrastructure facilities. The company is headquartered in Schwechat, Austria.
Full FGWLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.